1. Impact of tocilizumab on clinical outcomes in severe covid-19 patients and risk of secondary infection: A case-control study
- Author
-
Serra Ozel, Zekaver Odabasi, Mehtap Aydin, Uluhan Sili, Can Ilgin, Fethi Gül, Ismail Cinel, Volkan Korten, Buket Erturk Sengel, Luftiye Nilsun Altunal, Elif Tukenmez Tigen, Feyyaz Kabadayi, Sengel, Buket Erturk, Ozel, Serra, Gul, Fethi, Ilgin, Can, Tigen, Elif Tukenmez, Altunal, Luftiye Nilsun, Kabadayi, Feyyaz, Sili, Uluhan, Aydin, Mehtap, Odabasi, Zekaver, Cinel, Ismail, and Korten, Volkan
- Subjects
Mechanical ventilation ,IL-6 ,medicine.medical_specialty ,COVID-19,IL-6,SARS-CoV-2,Tocilizumab ,Coronavirus disease 2019 (COVID-19) ,SARS-CoV-2 ,business.industry ,medicine.medical_treatment ,Secondary infection ,Case-control study ,COVID-19 ,Tocilizumab ,EFFICACY ,RHEUMATOID-ARTHRITIS ,Tıp ,chemistry.chemical_compound ,chemistry ,Internal medicine ,Propensity score matching ,Cohort ,medicine ,Medicine ,In patient ,business - Abstract
Objective: This study aimed to identify the effect of tocilizumab (TCZ) on clinical outcomes in severe COVID-19 patients. Material and Methods: We included hospitalized COVID-19 patients with an initial WHO scale ≥4. We matched the patients with baseline characteristics by using propensity scores. Then, we selected patients with C-reactive protein levels above 30 and showing an upward trend. We assessed the effect of TCZ in patients on clinical outcomes by using Mann – Whitney U and Chi-square tests. Results: Of 200 patients who had an initial WHO scale ≥ 4, 42 (21%) were given TCZ in addition to standard of care (SOC). Twentyfive patients (50%) needed mechanical ventilation (MV) in the TCZ group, compared with 35 (21%) of 158 patients with SOC (p
- Published
- 2021